ahlam1399
07-20-2016, 03:43 AM
Zafgen to scrap lead obesity drug, shares slide
(Reuters) - Zafgen Inc said it was suspending the development of its lead obesity drug, beloranib, more than six months after the U.S. Food and Drug Administration asked the company to halt all tests on the drug following the death of two patients.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=EuHOi3ekZJM:7YxfUdYewPs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=EuHOi3ekZJM:7YxfUdYewPs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=EuHOi3ekZJM:7YxfUdYewPs:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=EuHOi3ekZJM:7YxfUdYewPs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=EuHOi3ekZJM:7YxfUdYewPs:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/EuHOi3ekZJM
(Reuters) - Zafgen Inc said it was suspending the development of its lead obesity drug, beloranib, more than six months after the U.S. Food and Drug Administration asked the company to halt all tests on the drug following the death of two patients.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=EuHOi3ekZJM:7YxfUdYewPs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=EuHOi3ekZJM:7YxfUdYewPs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=EuHOi3ekZJM:7YxfUdYewPs:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=EuHOi3ekZJM:7YxfUdYewPs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=EuHOi3ekZJM:7YxfUdYewPs:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/EuHOi3ekZJM